CN110687292A - Application of double negative B cell and regulatory B10 cell in preparation of autoimmune disease diagnostic reagent - Google Patents
Application of double negative B cell and regulatory B10 cell in preparation of autoimmune disease diagnostic reagent Download PDFInfo
- Publication number
- CN110687292A CN110687292A CN201911095085.5A CN201911095085A CN110687292A CN 110687292 A CN110687292 A CN 110687292A CN 201911095085 A CN201911095085 A CN 201911095085A CN 110687292 A CN110687292 A CN 110687292A
- Authority
- CN
- China
- Prior art keywords
- cells
- regulatory
- cell
- double negative
- diagnostic reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses application of double negative B cells and regulatory B10 cells in preparation of an autoimmune disease diagnostic reagent, wherein in the application, the diagnostic reagent can be used for respectively detecting the content of double negative B cells and the content of regulatory B10 cells of a patient. Double negative B cells: the regulatory B10 cell ratio is clearly different in normal humans and autoimmune patients, and this difference can be used to diagnose autoimmune diseases. The detection of the two cells only needs to sample peripheral blood and use flow cytometry, and the proportion is judged and the ratio is calculated very simply and conveniently; in addition, by setting a cut-off value (ROC curve analysis recommended value), higher accuracy can be ensured, the autoimmune disease can be determined without being comprehensively judged by combining other markers, good indication can be provided for diagnosis and drug treatment effect of the autoimmune disease, and clinical application is facilitated.
Description
Technical Field
The invention relates to the technical field of disease diagnosis, in particular to application of double negative B cells and regulatory B10 cells in preparation of an autoimmune disease diagnostic reagent.
Background
Autoimmune diseases (AID) are diseases caused by the immune dysfunction of the body caused by various factors, which leads to the immune reaction of the body to self antigens and the damage of self tissues. AID can be subdivided into more than 100 diseases, and no effective cure means exists at present, but timely and regular treatment can obviously improve symptoms and delay the progress of diseases, so the AID is very important for diagnosing the diseases.
Among the AID diseases, the most common are Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren Syndrome (SS), scleroderma, Idiopathic platelet purpura (ITP), Autoimmune hemolytic anemia (AIHA), etc., in which the patients of rheumatoid arthritis, systemic lupus erythematosus and Sjogren's syndrome are in the front.
The diagnosis of the above three diseases still has the problems of low sensitivity and poor specificity, and usually the detection result of one index needs to be combined with the detection results of other indexes to jointly judge and draw a conclusion.
AID disease is caused by the generation of autoantibodies which attack self tissues due to the imbalance of immune functions of the body, in other words, is a pathological state in which the homeostasis of autoimmunity is broken, and the biggest characteristic is the imbalance of immunity. For a long time, the relevant studies of immune imbalance in AID diseases have focused mainly on T cells, such as helper Th17 cells, follicular helper T cells (Tfh), regulatory T cells (Treg), etc. The role of B cells in the pathogenic process of AID has been mainly studied in the pathological processes such as autoantibody production, and there is no systematic study on immune imbalance.
Disclosure of Invention
At present, the relation between B cells and immune diseases is mostly focused on a single pathological process, and no combined diagnosis content exists.
In the research process, the applicant finds that double-negative B cells are obviously amplified in autoimmune diseases such as Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren Syndrome (SS) and the like. More importantly, in these diseases, double negative B cells: the regulatory B10 cell ratio was significantly increased (compared to the ratio of normal human and osteoarthritic double negative B cells: regulatory B10 cells). After treatment, double negative B cells: the regulatory B10 cell ratio returned to normal. It was shown that the detection of double negative B cells and regulatory B10 cells and the calculation of the ratio thereof can be an effective method for diagnosing autoimmune diseases.
Based on the above research conclusion, the invention provides the following technical scheme:
the invention provides application of double negative B cells and regulatory B10 cells in preparation of an autoimmune disease diagnostic reagent, wherein the diagnostic reagent can be used for respectively detecting the content of double negative B cells and the content of regulatory B10 cells of a patient so as to further calculate the ratio of the double negative B cells to the regulatory B10 cells.
By detecting the content thereof, and calculating double negative B cells: the ratio of B10 cells can be regulated to determine whether autoimmune diseases exist, which is very convenient.
Among these, double negative B cells are a group of cells lacking both IgD and the memory cell marker CD27 among the B cells undergoing immunoglobulin-type switching, and having the potential to produce autoantibodies. The regulatory B10 cells are a population of CD19+CD24hiCD27+Is a marked cell and has the function of immunoregulation. The imbalance of the ratio of the two is directly related to the onset of AID. The unbalanced ratio refers to the ratio of the double negative B cells to the regulatory B10 cells of a normal human, for example, the optional cutoff value is 0.8068 (more than this value, the diagnosis is positive).
Optionally or preferably, in the above application, the autoimmune disease is at least one of rheumatoid arthritis, systemic lupus erythematosus and sjogren's syndrome. The disease can be accurately judged as the result of the imbalance of the proportion of the two, but the specific types of the diseases cannot be further distinguished.
Alternatively or preferably, in the above application, the diagnostic reagent is an antibody capable of detecting double negative B cells and an antibody capable of detecting regulatory B10 cells. The antibody detection result can accurately calculate and compare double negative B cells: ratio of regulatory B10 cells.
Alternatively or preferably, in the above application, the detection target of the diagnostic reagent is human peripheral blood. The damage to the patient to be detected is small.
The invention also provides an autoimmune disease diagnostic reagent, which comprises an antibody for detecting double negative B cells and an antibody for detecting regulatory B cells.
Alternatively or preferably, in the above diagnostic reagent, the antibody is a fluorescent-labeled antibody for detecting double negative B cells: anti-human CD19, anti-human CD3, anti-human CD27 and anti-human IgD, and a fluorescent label for detecting regulatory B10 cells: anti-human CD19, anti-human CD3, anti-human CD24, and anti-human CD 27; the fluorescent marker of the double-negative B cell and the fluorescent marker of the regulatory B10 cell are matched to distinguish the double-negative B cell from the regulatory B10 cell.
Alternatively or preferably, in the diagnostic reagent, the antibody is CD19-APC/Cy7, CD3-PerCP/Cy5.5, CD27-APC and IgD-Pacific Blue for detecting double negative B cells, and CD19-APC/Cy7, CD3-PerCP/Cy5.5, CD24-FITC and CD27-APC for detecting regulatory B10 cells.
Alternatively or preferably, the diagnostic reagent further comprises a reference range of the content ratio of normal human double negative B cells to regulatory B cells.
Compared with the prior art, the invention has the following beneficial effects:
double negative B cells: the ratio of the regulatory B10 cells is obviously different between normal people and autoimmune patients, and the ratio can be judged by flow cytometry only by sampling peripheral blood, and the ratio is calculated, so that the detection is very simple and convenient; in addition, by setting a cut-off value (ROC curve analysis recommended value), higher accuracy can be ensured, the autoimmune disease can be determined without being comprehensively judged by combining other markers, good indication can be provided for diagnosis and drug treatment effect of the autoimmune disease, and clinical application is facilitated.
Drawings
FIG. 1 is a circle gate strategy for double negative B cells and regulatory B10 cells in the examples;
FIG. 2 is a representative graph of the flow results of double negative B cells and regulatory B10 cells in peripheral blood of normal Humans (HC) and autoimmune patients (RA, SLE, SS) and disease control Osteoarthritis (OA) patients in the examples;
FIG. 3 is a scatter plot of the statistics of the ratios of double negative B cells and regulatory B10 cells in peripheral blood of normal Humans (HC) to patients with autoimmune diseases (RA, SLE, SS) and disease control Osteoarthritis (OA) in the examples;
FIG. 4 is a schematic diagram showing the flow results of double negative B cells and regulatory B10 cells and their ratios in peripheral blood before and after treatment of RA patients in the example and a scattergram of statistical results;
FIG. 5 is a graph of ROC with RA, SLE, SS classified as disease group, HC and OA classified as control group;
in the above figures, DNB cells represent double negative B cells, and B10 cells represent regulatory B10 cells.
Detailed Description
The technical solutions of the present invention are explained and illustrated in detail below with reference to specific embodiments so that those skilled in the art can better understand the technical solutions of the present invention.
In the following examples, unless otherwise specified, all of the biomaterials and reagents used are commercially available or may be prepared according to conventional techniques, and the assay methods are also conventional in the art.
Example 1
Collecting peripheral blood samples of hospital inpatients: 2mL of venous blood was collected with an EDTA (ethylenediaminetetraacetic acid) anticoagulated blood collection tube.
mu.L of whole blood was taken in a flow tube (BD), and 3. mu.L each of the following flow antibodies was added: CD19-APC/Cy7, CD3-PerCP/Cy5.5, CD24-FITC, CD27-APC, IgD-Pacific Blue (all from eBioscience/Biolegend). After shaking and mixing, incubating for 15min at room temperature in dark, shaking and mixing, and incubating for 15min at room temperature in dark.
Adding 2mL of schizophyllum solution, mixing, and incubating at room temperature in dark for 10 min. Preparation method of schizophyllum commune liquidThe method comprises the following steps: 1 mL of 10 XFCMLysing solution (Union organism) plus 9mL of ddH2And O, and mixing uniformly.
Centrifuge at 1800rpm 5min, discard the supernatant, add 2mL PBS to resuspend the cells.
Centrifuging at 1800rpm × 5min, discarding the supernatant, adding 200 μ L of the fixative, resuspending the cells, and detecting by an up-flow cytometer.
In this example, the content of double negative B cells and the content of regulatory B10 cells in RA peripheral blood were measured in 77 cases of Rheumatoid Arthritis (RA), 12 cases of Systemic Lupus Erythematosus (SLE), 29 cases of Sjogren's Syndrome (SS), 32 cases of Osteoarthritis (OA), 56 cases of normal persons, and 14 cases of biological agent treatment. And the ratio of double negative B cells to regulatory B10 cells was calculated for each individual separately.
The gating strategy for double negative B cells and regulatory B10 cells is shown in figure 1.
Double negative B cells compared to normal Human (HC) and disease control Osteoarthritis (OA) patients: the proportion of the B10 cell ratio is obviously increased in autoimmune patients such as Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren Syndrome (SS), etc., see figure 2 and figure 3.
RA patients received anti-TNF-a biologic therapy, double negative B cells: the regulatory B10 cell ratio decreased and returned to normal levels, as shown in figure 4.
ROC curve analysis showed that double negative B cells: the regulatory B10 cell ratio was of good diagnostic value for autoimmune disease (RA, SS, SLE shown as disease group, HC and OA shown as control group) with a specificity of 93.18%, as shown in figure 5.
And the area under the curve (AUC) of the ROC curve is 0.834 and is more than 0.5, and the 95% Confidence Interval (CI) is 0.779-0.888, which shows that the reasonable setting of the Cut-off value has better prediction value. Cut-off value 0.8068 was recommended by ROC curve analysis, and corresponding sensitivity and specificity were calculated to be 49.15% and 93.18%, respectively, and Positive Predictive Value (PPV) and Negative Predictive Value (NPV) were 90.62% and 57.74%, respectively, showing potential diagnostic value.
The inventive concept is explained in detail herein using specific examples, which are given only to aid in understanding the core concepts of the invention. It should be noted that any obvious modifications, equivalents or other improvements, such as the use of plasma cells to B10 cell ratio regulator in the preparation of diagnostic reagents for autoimmune diseases, which would occur to one skilled in the art without departing from the spirit of the invention, are intended to be included within the scope of the present invention.
Claims (8)
1. The application of double negative B cell and regulatory B10 cell in preparing autoimmune disease diagnostic reagent can detect the content of double negative B cell and regulatory B10 cell in patient separately to further calculate the ratio.
2. The use of claim 1, wherein the autoimmune disease is at least one of rheumatoid arthritis, systemic lupus erythematosus, and sjogren's syndrome.
3. The use of claim 1, wherein the diagnostic reagent is an antibody capable of detecting double negative B cells and an antibody capable of detecting regulatory B10 cells.
4. The use according to claim 1, wherein the test object of the diagnostic reagent is human peripheral blood.
5. An autoimmune disease diagnostic reagent comprising an antibody for detecting double negative B cells and an antibody for detecting regulatory B cells.
6. The diagnostic reagent of claim 5, wherein the antibody is fluorescently labeled for detecting double negative B cells: anti-human CD19, anti-human CD3, anti-human CD27 and anti-human IgD, and a fluorescent label for detecting regulatory B10 cells: anti-human CD19, anti-human CD3, anti-human CD24, and anti-human CD 27; the fluorescent marker of the double-negative B cell and the fluorescent marker of the regulatory B10 cell are matched to distinguish the double-negative B cell from the regulatory B10 cell.
7. The diagnostic reagent of claim 6, wherein the antibody is CD19-APC/Cy7, CD3-PerCP/Cy5.5, CD27-APC and IgD-Pacific Blue for detecting double negative B cells, and CD19-APC/Cy7, CD3-PerCP/Cy5.5, CD24-FITC and CD27-APC for detecting regulatory B10 cells.
8. The diagnostic reagent of claim 5, further comprising a reference range of the ratio of normal human double negative B cell to regulatory B cell content.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911095085.5A CN110687292A (en) | 2019-11-11 | 2019-11-11 | Application of double negative B cell and regulatory B10 cell in preparation of autoimmune disease diagnostic reagent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911095085.5A CN110687292A (en) | 2019-11-11 | 2019-11-11 | Application of double negative B cell and regulatory B10 cell in preparation of autoimmune disease diagnostic reagent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110687292A true CN110687292A (en) | 2020-01-14 |
Family
ID=69116165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911095085.5A Pending CN110687292A (en) | 2019-11-11 | 2019-11-11 | Application of double negative B cell and regulatory B10 cell in preparation of autoimmune disease diagnostic reagent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110687292A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130136754A1 (en) * | 2010-08-04 | 2013-05-30 | Thomas F. Tedder | Regulatory b cells and their uses |
| CN104360053A (en) * | 2014-09-22 | 2015-02-18 | 重庆医科大学附属儿童医院 | B lymphocyte immunophenotyping method and kit |
| CN104360050A (en) * | 2014-09-22 | 2015-02-18 | 重庆医科大学附属儿童医院 | Method for lymphocyte subsets and kit thereof |
| CN107209101A (en) * | 2014-10-30 | 2017-09-26 | 鹿特丹伊拉斯谟大学医疗中心 | For the reagent of diagnosing primary immune deficiency, method and kit |
| CN109254147A (en) * | 2018-10-12 | 2019-01-22 | 东莞暨南大学研究院 | Human peripheral blood immune cell function fully assesses kit and appraisal procedure |
| CN109406775A (en) * | 2018-10-12 | 2019-03-01 | 东莞市暨科生物科技有限公司 | Autoimmune disease patient's immune function assesses kit and appraisal procedure |
-
2019
- 2019-11-11 CN CN201911095085.5A patent/CN110687292A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130136754A1 (en) * | 2010-08-04 | 2013-05-30 | Thomas F. Tedder | Regulatory b cells and their uses |
| CN104360053A (en) * | 2014-09-22 | 2015-02-18 | 重庆医科大学附属儿童医院 | B lymphocyte immunophenotyping method and kit |
| CN104360050A (en) * | 2014-09-22 | 2015-02-18 | 重庆医科大学附属儿童医院 | Method for lymphocyte subsets and kit thereof |
| CN107209101A (en) * | 2014-10-30 | 2017-09-26 | 鹿特丹伊拉斯谟大学医疗中心 | For the reagent of diagnosing primary immune deficiency, method and kit |
| CN109254147A (en) * | 2018-10-12 | 2019-01-22 | 东莞暨南大学研究院 | Human peripheral blood immune cell function fully assesses kit and appraisal procedure |
| CN109406775A (en) * | 2018-10-12 | 2019-03-01 | 东莞市暨科生物科技有限公司 | Autoimmune disease patient's immune function assesses kit and appraisal procedure |
Non-Patent Citations (5)
| Title |
|---|
| RITA A. MOURA等: "B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis", 《PLOS ONE》 * |
| 刘洪江等: "类风湿关节炎患者外周血B10细胞高表达核因子κB受体活化因子配体", 《北京大学学报（医学版）》 * |
| 周儒: "老年胃癌患者手术治疗风险与疗效评价及巨噬细胞相关集落刺激因子作为新型肿瘤标志物的探索", 《中国优秀博硕士学位论文全文数据库(博士) 医药卫生科技辑》 * |
| 屠斌等: "尿癌胚抗原RIA对膀胱癌诊断的实用价值", 《中华泌尿外科杂志》 * |
| 汤自洁等: "血清Cyfra21-1、CEA及SF联合检测在非小细胞型肺癌中的临床应用", 《重庆医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8053200B2 (en) | Monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products | |
| US9395365B2 (en) | Detection of infectious disease in a human or animal by measuring specific phagocytosis in a thin film sample of their anticoagulated blood | |
| CN1339108A (en) | Method for diagnosing and distinguishing stroke | |
| CN106461675A (en) | Method for diagnosing tuberculosis | |
| CN109187941A (en) | Application of the CD4+CD70+T cell subsets in preparation auxiliary diagnosis pole aplastic anaemia kit | |
| Lucchese et al. | IFAT and ELISA phase I/phase II as tools for the identification of Q fever chronic milk shedders in cattle | |
| JP5805518B2 (en) | Multiplex colorectal cancer marker panel | |
| CN109991417B (en) | Immune marker for tuberculosis and application | |
| CN103760345B (en) | A kind of kit and application thereof utilizing peripheral blood detection m tuberculosis infection | |
| Desai et al. | C-reactive protein, immature to total neutrophil ratio and micro ESR in early diagnosis of neonatal sepsis | |
| CN109425743A (en) | Detect the microballoon double-antibody sandwich detection method and kit of solubility FAM19A4 albumen | |
| WO2021250323A1 (en) | Anti-cox-2 autoantibody as a diagnostic marker, and methods, kits and uses related thereto | |
| CN110687292A (en) | Application of double negative B cell and regulatory B10 cell in preparation of autoimmune disease diagnostic reagent | |
| Zhang et al. | Clinical value of alkaline phosphatase on the surface membrane of neutrophils for prediction of bacteremia in patients with systemic inflammatory response syndrome | |
| CN109781987A (en) | Terminal effector T cell subgroup is preparing the application in aided assessment aplastic amenia feelings degree kit | |
| CN111504886B (en) | Application of a group of molecules in preparation of auxiliary diagnosis reagent or kit for new coronary pneumonia | |
| CN114636826A (en) | Application of CD177+ neutrophils in preparation of detection product for neonatal necrotizing enterocolitis | |
| AU2022436042A1 (en) | Method for detecting a phenotype and a function of a cd141+ dendritic cell subset and kit for use | |
| CN103675293B (en) | The purposes of Rv3872, Rv0164 and/or Rv1926c albumen in the phthisical product of preparation diagnostic activities | |
| Iddles et al. | Evaluation of the immature granulocyte count in the diagnosis of sepsis using the sysmex XE-2100 analyser | |
| CN105671188A (en) | Molecular marker and primer set for diagnosing Mycobacterium tuberculosis infection, and application thereof | |
| WO2018170875A1 (en) | Pet disease prevention and diagnosis method based on nanometer-scale gene anchoring and microfluidic immunological agglutination technology | |
| El-Gendy et al. | Diagnosis of spontaneous bacterial peritonitis | |
| Ravindran et al. | β‐thalassaemia carrier detection by ELISA: A simple screening strategy for developing countries | |
| CN103336127A (en) | Indicator and diagnostic agent of early-stage hepatopathy, hepatic fibrosis and hepatic cirrhosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200114 |